Compare MGF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGF | MGNX |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 115.8M |
| IPO Year | N/A | 2013 |
| Metric | MGF | MGNX |
|---|---|---|
| Price | $3.02 | $1.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 104.4K | ★ 955.6K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 7.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.91 | $0.99 |
| 52 Week High | $3.46 | $3.00 |
| Indicator | MGF | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.06 |
| Support Level | N/A | $1.66 |
| Resistance Level | N/A | $1.97 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 29.58 |
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.